Drugs / Aza-TdC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03366116 | Nov 2018 → Sep 2026 overdue | neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aza-TdC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03366116 ↗ |
| Known as | 5-aza-4'-thio-2'- deoxycytidine | “The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (Aza-TdC) is incorporated into DNA” NCT03366116 ↗ |
| Action | Inhibit | “Treatment with Aza-TdC is anticipated to yield inhibition of tumor growth due to DNMT1 depletion” NCT03366116 ↗ |
| Modality | Small molecule | “The nucleoside analog” NCT03366116 ↗ |
| Route | Oral | “Aza-TdC will be administered orally once a day” NCT03366116 ↗ |
| Target | DNMT1 | “due to DNMT1 depletion” NCT03366116 ↗ |